RxDoctor Payments Data

Ibrahim Humaisan

Physician Assistant · Dearborn, MINPI 1326664194

Payments from drug & device makers

$2,456in general payments, 2019–2025

Across 85 payments — averaging $28.89 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AstraZeneca$781
  • GSK$585
  • Novo Nordisk$231
  • Exact Sciences$207
  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$202
  • Lilly USA, LLC$119
  • plus $331 from 6 others

What the payments were for

  • Food & beverage$2,456100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,456 in reported general payments places this provider in the 85th percentile of 5,453 physician assistant providers in Michigan.

See all physician assistant providers in Michigan

Medicare billing

Part B allowed, 2024
$10,940
Medicare patients
79
Services billed
247

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
FarxigaDapagliflozin Propanediol55$31,672
Trelegy ElliptaFluticasone/Umeclidin/Vilanter45$28,618
OzempicSemaglutide23$23,502
JanuviaSitagliptin Phosphate29$20,205
MounjaroTirzepatide15$15,727
JardianceEmpagliflozin19$11,498
EliquisApixaban19$10,817
DapagliflozinDapagliflozin Propanediol16$8,958
XareltoRivaroxaban11$6,205
LinzessLinaclotide11$5,952
TrintellixVortioxetine Hydrobromide11$5,040
Albuterol Sulfate HfaAlbuterol Sulfate131$4,308
Esomeprazole Magnesium100$4,236
Diclofenac Sodium137$3,985
SymbicortBudesonide/Formoterol Fumarate11$2,975

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
AstraZenecaFarxiga, Symbicort$781$34,64766 claims
GSKTrelegy Ellipta$585$28,61845 claims
Novo NordiskOzempic$231$23,50223 claims
Lilly USA, LLCMounjaro$119$15,72715 claims
PfizerEliquis$47$10,81719 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 5,453 physician assistant providers in Michigan.

Other physician assistant in Dearborn

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →